82 related articles for article (PubMed ID: 22931245)
1. Growth inhibition and chemosensitization of human carcinoma cells by human serum albumin-coated liposomal antisense oligodeoxyribonucleotide against bcl-2.
Weecharangsan W; Lee RJ
Drug Deliv; 2012 Aug; 19(6):292-7. PubMed ID: 22931245
[TBL] [Abstract][Full Text] [Related]
2. Efficient delivery of antisense oligodeoxyribonucleotide g3139 by human serum albumin-coated liposomes.
Weecharangsan W; Yu B; Zheng Y; Liu S; Pang JX; Lee LJ; Marcucci G; Lee RJ
Mol Pharm; 2009; 6(6):1848-55. PubMed ID: 19725564
[TBL] [Abstract][Full Text] [Related]
3. Disulfide-linked liposomes: effective delivery vehicle for Bcl-2 antisense oligodeoxyribonucleotide G3139.
Weecharangsan W; Yu B; Liu S; Pang JX; Lee LJ; Marcucci G; Lee RJ
Anticancer Res; 2010 Jan; 30(1):31-7. PubMed ID: 20150614
[TBL] [Abstract][Full Text] [Related]
4. Co-delivery of plasmid DNA and antisense oligodeoxyribonucleotide into human carcinoma cells by cationic liposomes.
Weecharangsan W; Opanasopit P; Yingyongnarongkul BE; Kewsuwan P; Lee RJ
Curr Pharm Biotechnol; 2014; 15(9):790-9. PubMed ID: 25307014
[TBL] [Abstract][Full Text] [Related]
5. Efficient delivery of an antisense oligodeoxyribonucleotide formulated in folate receptor-targeted liposomes.
Chiu SJ; Marcucci G; Lee RJ
Anticancer Res; 2006; 26(2A):1049-56. PubMed ID: 16619505
[TBL] [Abstract][Full Text] [Related]
6. Increase of therapeutic effects by treating melanoma with targeted combinations of c-myc antisense and doxorubicin.
Pastorino F; Mumbengegwi DR; Ribatti D; Ponzoni M; Allen TM
J Control Release; 2008 Feb; 126(1):85-94. PubMed ID: 18166243
[TBL] [Abstract][Full Text] [Related]
7. Molecular and pharmacokinetic properties associated with the therapeutics of bcl-2 antisense oligonucleotide G3139 combined with free and liposomal doxorubicin.
Lopes de Menezes DE; Hudon N; McIntosh N; Mayer LD
Clin Cancer Res; 2000 Jul; 6(7):2891-902. PubMed ID: 10914739
[TBL] [Abstract][Full Text] [Related]
8. [The inhibitory effect of bcl-2 antisense oligodeoxynucleotide/RNA on the growth of cervical carcinoma in vitro].
Mi R; Wang H; Qu Q
Zhonghua Fu Chan Ke Za Zhi; 2000 Feb; 35(2):105-8. PubMed ID: 11809111
[TBL] [Abstract][Full Text] [Related]
9. Targeted liposomal c-myc antisense oligodeoxynucleotides induce apoptosis and inhibit tumor growth and metastases in human melanoma models.
Pastorino F; Brignole C; Marimpietri D; Pagnan G; Morando A; Ribatti D; Semple SC; Gambini C; Allen TM; Ponzoni M
Clin Cancer Res; 2003 Oct; 9(12):4595-605. PubMed ID: 14555535
[TBL] [Abstract][Full Text] [Related]
10. Targeted delivery of antisense oligodeoxynucleotide and small interference RNA into lung cancer cells.
Li SD; Huang L
Mol Pharm; 2006; 3(5):579-88. PubMed ID: 17009857
[TBL] [Abstract][Full Text] [Related]
11. G3139 antisense oligonucleotide directed against antiapoptotic Bcl-2 enhances doxorubicin cytotoxicity in the FU-SY-1 synovial sarcoma cell line.
Joyner DE; Albritton KH; Bastar JD; Randall RL
J Orthop Res; 2006 Mar; 24(3):474-80. PubMed ID: 16450387
[TBL] [Abstract][Full Text] [Related]
12. Antisense oligodeoxyribonucleotide down-regulation of bcl-2 gene expression inhibits growth of the low-grade non-Hodgkin's lymphoma cell line WSU-FSCCL.
Smith MR; Abubakr Y; Mohammad R; Xie T; Hamdan M; al-Katib A
Cancer Gene Ther; 1995 Sep; 2(3):207-12. PubMed ID: 8528964
[TBL] [Abstract][Full Text] [Related]
13. Antitumor efficacy of bcl-2 and c-myc antisense oligonucleotides in combination with cisplatin in human melanoma xenografts: relevance of the administration sequence.
Zupi G; Scarsella M; Semple SC; Mottolese M; Natali PG; Leonetti C
Clin Cancer Res; 2005 Mar; 11(5):1990-8. PubMed ID: 15756025
[TBL] [Abstract][Full Text] [Related]
14. Modulation of malignant B cell activation and apoptosis by bcl-2 antisense ODN and immunostimulatory CpG ODN.
Jahrsdörfer B; Jox R; Mühlenhoff L; Tschoep K; Krug A; Rothenfusser S; Meinhardt G; Emmerich B; Endres S; Hartmann G
J Leukoc Biol; 2002 Jul; 72(1):83-92. PubMed ID: 12101266
[TBL] [Abstract][Full Text] [Related]
15. Effect of MDR1 phosphorothioate antisense oligodeoxynucleotides in multidrug-resistant human tumor cell lines and xenografts.
Ramachandran C; Wellham LL
Anticancer Res; 2003; 23(3B):2681-90. PubMed ID: 12894558
[TBL] [Abstract][Full Text] [Related]
16. [Bcl-2 antisense oligodeoxyribonucleotide increases apoptosis of lung carcinoma cells induced by cisplatin].
Ouyang N; Ran P; Qiu Z
Zhonghua Jie He He Hu Xi Za Zhi; 2000 Dec; 23(12):722-4. PubMed ID: 11778475
[TBL] [Abstract][Full Text] [Related]
17. [Apoptosis increased by bcl-2 antisense ODN in MCF-7 cell line].
Zheng J; Yao Z
Zhonghua Wai Ke Za Zhi; 1999 Jul; 37(7):418-20. PubMed ID: 11829877
[TBL] [Abstract][Full Text] [Related]
18. Chemosensitization of carcinoma cells using epithelial cell adhesion molecule-targeted liposomal antisense against bcl-2/bcl-xL.
Hussain S; Plückthun A; Allen TM; Zangemeister-Wittke U
Mol Cancer Ther; 2006 Dec; 5(12):3170-80. PubMed ID: 17172421
[TBL] [Abstract][Full Text] [Related]
19. Vascular targeting of doxorubicin using cationic liposomes.
Wu J; Lee A; Lu Y; Lee RJ
Int J Pharm; 2007 Jun; 337(1-2):329-35. PubMed ID: 17275230
[TBL] [Abstract][Full Text] [Related]
20. Synergistic Inhibition of Human Carcinoma Cell Growth
Weecharangsan W; Opanasopit P; Niyomtham N; Yingyongnarongkul BE; Kewsuwan P; Lee RJ
Anticancer Res; 2017 Nov; 37(11):6335-6340. PubMed ID: 29061817
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
